The same molecule, three different injection routes, three different experiences. Patients researching NAD+ injection protocols quickly run into a confusing mix of marketing language: clinics selling IV drips, telehealth programs offering subcutaneous home protocols, and a smaller set of practices using intramuscular delivery. The differences between these routes are not aesthetic. They produce measurably different pharmacokinetic profiles, different side effect patterns, and different clinical fits. This article compares them on the dimensions that actually matter for a patient deciding which protocol to start.
The short version: NAD+ IV vs subcutaneous is not a question of which works and which does not — both work — it is a question of which delivery profile matches the patient's clinical picture, schedule, and tolerance. The IM route is a less common third option that occupies a middle position. Understanding the trade-offs lets a patient have a real conversation with a clinician about which route to start with rather than defaulting to whichever the closest clinic happens to sell.
Bioavailability and concentration profile by route
All three injection routes bypass the gut and first-pass liver metabolism that defeat oral NAD+ supplementation. On total bioavailability — the area under the blood concentration curve — IV and subcutaneous are both effectively complete. IM sits close behind. The molecule reaches circulation in essentially full dose by all three routes. What differs is the shape of the concentration-time curve.
IV administration delivers the entire dose into venous circulation as a single bolus or controlled infusion. Peak blood concentration is reached at the end of the infusion. The curve then declines as the molecule distributes into tissues and is consumed. A typical clinical IV NAD+ session might run 250 to 500 mg over 60 to 180 minutes, producing the highest blood concentration of any route. The peak is short; the tissue exposure depends on what the cells do with the molecule once it arrives.
Subcutaneous injection deposits the dose in the fatty layer below the skin, from which it absorbs gradually into local capillaries. Peak concentration is reached over a longer window — typically one to three hours — and the curve is flatter and broader than IV. The total exposure is similar but distributed differently in time. Prescribed NAD+ subcutaneous dosing typically falls in the 50 to 150 mg per injection range, administered two to five times per week to maintain a sustained tissue concentration.
IM injection delivers the dose into muscle tissue, where blood flow is higher than subcutaneous fat. Absorption is faster than SubQ but slower than IV. Peak is typically reached in 30 to 90 minutes. IM doses in NAD+ protocols are usually similar to SubQ dosing, in the 50 to 150 mg range. IM is less commonly used for NAD+ specifically because the SubQ route already provides good bioavailability with simpler self-administration.
Side effect patterns by route
The side effect profile of NAD+ is dose-dependent and concentration-dependent, which means the route matters because the route shapes the concentration curve.
IV at higher infusion rates produces the most pronounced acute side effects. Patients commonly report warmth, flushing, chest pressure, occasional nausea, and a body-wide sensation many describe as feeling the dose travel through them. These effects diminish substantially when the infusion is slowed; a 250 mg dose delivered over two hours is much better tolerated than the same dose over 30 minutes. The trade-off is appointment length and cost per session. Some clinics now run extended-rate infusions specifically to reduce the acute discomfort.
SubQ injection produces a different pattern. Local site reactions — warmth, mild redness, occasional welts that resolve within hours — are the most common complaint. Systemic flush can occur at higher doses but is generally milder than IV because the absorption is slower. Patients typically describe SubQ NAD+ as well-tolerated after the first one or two injections, particularly if they alternate sites.
IM injection sits between the two. Less local reaction than SubQ at the same dose, less systemic flush than IV at the same dose. The trade-off is that IM injection is more painful at the moment of administration than SubQ for many patients, and the muscle tissue can be sore for 24 to 48 hours afterward at higher doses.
At-home self-administration
The practical question for many patients is which route they can run themselves at home and which requires a clinic visit. NAD+ at home is essentially a SubQ protocol. Subcutaneous self-injection is the same technique used for insulin, GLP-1 medications, and a wide range of other peptides. With brief training a patient can run the protocol themselves on a defined schedule. The needle is small, the depth is shallow, and the technique is well-established.
IV NAD+ requires venous access, infusion equipment, and clinical oversight. It is not a home protocol. Patients who prefer IV typically schedule sessions at a clinic on a less frequent cadence — once a week or once a month — rather than the more frequent cadence of SubQ.
IM injection is technically possible to self-administer but is less commonly trained for NAD+ specifically. Most home protocols default to SubQ for this reason. If a clinical reason emerges to use IM, the clinician will train the patient on technique and site rotation.
The practical consequence of this division: clinically supervised home dosing has effectively standardized on subcutaneous NAD+ as the default route for ongoing therapy. Licensed peptide injection programs across telehealth use SubQ for NAD+, growth hormone secretagogues, and most peptide protocols precisely because the route is safe, effective, and self-administrable.
Which route fits which patient
A patient who wants a single high-impact session and is willing to schedule a clinic visit may prefer IV. The peak concentration is the highest of the three routes, and many patients describe a strong subjective effect that is harder to achieve with SubQ. The cost per session is higher, and the scheduling burden is real, but for some patients the experience is worth it.
A patient who wants a sustained protocol over weeks or months — the most common use case in longevity and recovery work — typically does better on SubQ at home. The frequency is higher, the dose per session is lower, and the cumulative tissue exposure builds across the protocol. Cost per dose is lower than IV, and there is no clinic visit per session.
A patient who is starting with a known low-NAD+ picture and wants to establish concentration quickly might begin with IV and transition to SubQ for maintenance. The clinician makes this call based on the clinical picture. Some protocols use the opposite sequence — start SubQ, add an IV session if response plateaus.
Cadence and titration
Whatever the route, NAD+ protocols are titrated against patient response. The clinician starts at a conservative dose, observes how the patient tolerates it, and adjusts based on energy, recovery, sleep, and any side effects. Higher-dose protocols are not better by definition; the right dose is the lowest amount that produces the response the patient is targeting.
For SubQ specifically, this means starting at the lower end of the typical range and increasing only if needed. Many patients find their effective dose in the first month and hold it indefinitely. Others step up over the first few weeks until they reach a plateau of response.
The cadence is similarly individualized. Two doses per week is a common starting point. Some patients move to three or four doses per week if response warrants. Daily SubQ NAD+ is unusual at higher concentrations because of the cumulative side effect burden, but lower-dose daily protocols exist for specific clinical pictures.
How TelePeptide handles route selection
Route selection is a clinical decision, not a menu item. The licensed clinician reviews the patient's history, goals, schedule, and any prior NAD+ exposure, and recommends the route that fits. Most patients on the Recovery & Performance track end up on SubQ at home; some begin with an IV loading session. The protocol is adjusted as the response is observed. Compounded preparations are sourced from licensed 503A pharmacies. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.
FAQ
Common questions
What is the difference between subcutaneous, IV, and IM administration?
Subcutaneous (SubQ) injection deposits the medication in the fatty layer just under the skin, from which it absorbs gradually into local capillaries. Intravenous (IV) administration delivers the medication directly into a vein for immediate systemic distribution. Intramuscular (IM) injection places it into muscle tissue, where it absorbs faster than subcutaneous but slower than IV. Each route produces a different concentration-time curve. IV gives the highest peak concentration. SubQ gives a more gradual rise and a longer plateau. IM sits between the two. The choice between them depends on what the protocol is trying to accomplish.
Which route delivers the most NAD+ per dose?
On peak blood concentration, IV is highest because the entire dose enters circulation in a single bolus. On total bioavailability — the area under the concentration curve — IV and SubQ are both effectively complete, since neither passes through the gut or first-pass liver metabolism. IM is also high. The difference is the shape of the curve, not the total amount delivered. For most clinical purposes the gradual SubQ profile is preferred because it minimizes the side effects associated with rapid concentration spikes and produces sustained tissue exposure across the day.
Why is subcutaneous NAD+ the most common at-home protocol?
Three reasons. First, it can be self-administered safely with brief training, which IV cannot. Second, the slower absorption profile reduces flushing, warmth, and nausea that some patients experience with rapid IV NAD+ infusions. Third, the cadence — typically two to five subcutaneous doses per week — lets a clinician titrate to patient-reported response without the logistical burden of infusion appointments. The trade-off is that SubQ takes longer to reach peak concentration. For most patients optimizing for sustained mitochondrial support, that trade-off favors the home protocol.
Are there side effects unique to one route?
Yes. IV NAD+ at clinical infusion rates produces the most pronounced acute effects: warmth, flushing, chest pressure, occasional nausea, and a sensation many patients describe as feeling the molecule travel through them. Slower infusion rates reduce these effects but extend appointment length, sometimes to multiple hours. SubQ injection produces local site reactions — warmth, mild redness, occasional welts — and a milder systemic flush at higher doses. IM injection sits between the two, with less local reaction than SubQ but more than IV at the dose site, and less systemic flush than IV at the same dose.
Can someone switch routes during their protocol?
Yes, and clinicians sometimes recommend it. A patient might begin with an IV loading session to establish a high tissue concentration quickly, then move to subcutaneous maintenance at home for sustained dosing. Alternatively, a patient on subcutaneous protocol who has plateaued may benefit from a single IV session as a reset, then return to home dosing. The route is not a permanent commitment. It is a clinical decision that can be revisited as the protocol progresses and the patient response is observed.
Next Step
Talk to a TelePeptide Clinician
A licensed clinician will review your goals and recommend the right protocol — peptide wellness, recomposition, or supervised weight loss. No insurance, no waiting room.
TelePeptide offers direct-pay telehealth services. All medications are compounded by licensed 503A pharmacies. Prescribing decisions are made solely by licensed clinicians based on individual medical necessity. These statements have not been evaluated by the FDA. Compounded medications are not FDA-approved.